Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Expenses (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Operating Expenses for 13 consecutive years, with $58.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 10.38% to $58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $223.3 million through Dec 2025, down 1.21% year-over-year, with the annual reading at $223.3 million for FY2025, 1.21% down from the prior year.
  • Operating Expenses hit $58.6 million in Q4 2025 for Coherus Oncology, up from $55.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $250.4 million in Q1 2021 to a low of $49.9 million in Q2 2024.
  • Historically, Operating Expenses has averaged $98.4 million across 5 years, with a median of $98.5 million in 2022.
  • Biggest five-year swings in Operating Expenses: soared 232.48% in 2021 and later crashed 66.89% in 2024.
  • Year by year, Operating Expenses stood at $112.9 million in 2021, then fell by 14.23% to $96.8 million in 2022, then soared by 65.66% to $160.4 million in 2023, then plummeted by 66.89% to $53.1 million in 2024, then grew by 10.38% to $58.6 million in 2025.
  • Business Quant data shows Operating Expenses for CHRS at $58.6 million in Q4 2025, $55.9 million in Q3 2025, and $55.7 million in Q2 2025.